Carcinoid syndrome caused by a serotonin-secreting pituitary tumour

European Journal of Endocrinology

Volumn 170, Issue 2, 2014, Pages

  Lynggard, Louise A ^a   Nielsen, Eigil Husted ^a   Laurberg, Peter ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893696627     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0622     Document Type: Article

References (19)

1. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plöckinger U, Salazar R et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012 95 135-156. (doi:10.1159/000335629)
2. O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, Pape UF & Plöckinger U & Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009 90 194-202. (doi:10.1159/000225948)
3. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Gave G, Kaltsas GA, Krenning EP et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 2008 1 61-72. (doi:10.1016/S1470- 2045(07)70410-2)
4. Srivastava A & Hornick JL. Immunohistochemical staining for CDX.-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. American Journal of Surgical Pathology 2009 33 626-632. (doi:10.1097/PAS. 0b013e31818d7d8b)
5. Graham GW, Unger BP & Coursin DB. Perioperative management of selected endocrine disorders. International Anesthesiology Clinics 2000 38 31-67. (doi:10.1097/00004311-200010000-00004)
6. Hemminki K & Li X. Incidence trends and risk factors of carcinoid tumours. A national epidemiologic study from Sweden. Cancer 2001 92 2204-2210. (doi:10.1002/1097-0142(20011015)92:8!2204::AIDCNCR1564O3.0. CO;2-R)
7. Modlin IM & Sandor A. An analysis of 8305 cases of carcinoid tumours. Cancer 1997 79 813-829. (doi:10.1002/(SICI)1097-0142(19970215)79:4!813: :AID-CNCR19O3.0.CO;2-2)
8. Godwin JD. Carcinoid tumours: an analysis of 2837 cases. Cancer 1975 79 560-569. (doi:10.1002/1097-0142(197508)36:2!560::AIDCNCR2820360235O3.0. CO;2-4)
9. Nassiri F, Cusimano M, Rotondo F, Horveth E & Kovacs K. Neuroendocrine tumour of unknown origin metastasizing to a growth hormone-secreting pituitary adenoma. World Neurosurgery 2012 77 201.e9-201.e12. (doi:10.1016/j.wneu.2011.02.017)
10. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder WW & Plöckinger U & Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009 90 220-226. (doi:10.1159/000225951)
11. Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, Del Basso De Caro ML, Milone F, Scarpelli G, Masone S et al. The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. Journal of Endocrinological Investigation 2008 31 277-286.
12. Hage R, Brutel de la Riviére A, Seldenrijk CA & Bosch JMM. Update in pulmonary carcinoid tumours: a review article. Annals of Surgical Oncology 2003 10 697-704. (doi:10.1245/ASO.2003.09.019)
13. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumours. Journal of Clinical Endocrinology and Metabolism 2001 862 895-902. (doi:10.1210/jc.86.2.895)
14. Balon HR, Brown TL, Goldsmith SJ, Silberstein EB, Krenning EP, Lang O, Dillehay G, Tarrance J, Johnson M, Stabin MG et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. Journal of Nuclear Medicine Technology 2011 39 317-324. (doi:10.2967/jnmt.111.098277)
15. Binderup T, Knigge U, Loft A, Federspiel B & Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clinical Cancer Research 2010 16 978-985. (doi:10.1158/1078-0432.CCR-09-1759)
16. Menda Y, Ponto LL, Schultz MK, Zamba GK, Watkins GL, Bushnell DL, Madsen MT, Sunderland JJ, Graham MM, O'Dorisio TM et al. Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors. Pancreas 2013 42 937-943. (doi:10.1097/MPA.0b013e318287ce21)
17. Toth-Fejel S & Pommier RF. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumours. American Journal of Surgery 2004 187 575-579. (doi:10.1016/j.amjsurg. 2004.01.019)
18. de Herder WW, Kwekkeboom DJ, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ & Krenning EP. Somatostatin receptor imaging for neuroendocrine tumors. Pituitary 2006 9 243-248. (doi:10.1007/s11102-006-0270-5)
19. Nadler A, Cukier M, Rowsell C, Kamali S, Feinberg Y, Singh S & Law CH. Ki-67 is a reliable pathological grading marker for neuroendocrine tumors. Virchows Archiv 2013 462 501-505. (doi:10.1007/s00428-013-1410-8)